Clinical Trial Update: A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's Disease [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 gene therapy trial (CAP-003) in adults with GBA1-associated Parkinson's disease has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• CAP-003

Snippet

Sponsor: Capsida Biotherapeutics, Inc. | Conditions: GBA1 Parkinson Disease | Phase 1, Phase 2 | Status: SUSPENDED